文献速递妇科

尼拉帕利治疗铂敏感复发性卵巢癌的真实世界数据:MITO 组的多中心经验

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
PubMed 文献 · Gynecol Oncol · 2024-01-25

该多中心回顾性/前瞻性观察研究纳入意大利扩展准入计划中铂敏感复发性卵巢癌患者,评估尼拉帕利维持治疗的真实世界疗效与安全性。304例可评估患者中260例(85%)为BRCA野生型,36例(11.9%)为BRCA突变;BRCA野生型与突变型中位无进展生存期分别为9.1个月(95%CI:6.9-11.2)和10.3个月(95%CI:7.0-13.5),中位总生存期分别为41.7个月(95%CI:31.6-41.9)和34.6个月(95%CI:N.E.)。结论认为尼拉帕利在真实世界铂敏感复发性卵巢癌维持治疗中有效且耐受良好。

要点

  • 304例可评估患者中,BRCA野生型260例(85%),BRCA突变型36例(11.9%)。
  • BRCA野生型中位PFS为9.1个月(95%CI:6.9-11.2),BRCA突变型为10.3个月(95%CI:7.0-13.5)。
  • BRCA野生型中位OS为41.7个月(95%CI:31.6-41.9),BRCA突变型为34.6个月(95%CI:N.E.)。

核心结论

  • 真实世界数据提示,尼拉帕利用于铂敏感复发性卵巢癌维持治疗有效且耐受良好。

研究设计与样本

  • 回顾性/前瞻性观察性研究,纳入意大利扩展准入计划中铂敏感复发性卵巢癌接受尼拉帕利维持治疗的患者,共304例可评估。

主要发现

  • 260例(85%)为BRCA野生型,36例(11.9%)为BRCA突变型。
  • BRCA野生型中位PFS为9.1个月(95%CI:6.9-11.2),BRCA突变型为10.3个月(95%CI:7.0-13.5)。
  • BRCA野生型中位OS为41.7个月(95%CI:31.6-41.9),BRCA突变型为34.6个月(95%CI:N.E.)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: PARP (poly adenosine diphosphate [ADP]-ribose polymerase) inhibitors are approved as maintenance therapy in platinum sensitive ovarian cancer (OC), in first line and in the recurrent setting, regardless of BRCA mutational status. Real-world data after the introduction of these agents are needed to evaluate whether the benefit observed in phase III randomized clinical trials can be translated into clinical practice. The aim of our study was to provide real-life data on efficacy and safety of niraparib administered as maintenance in platinum sensitive relapsed OC patients (PSROC). METHODS: This retrospective/prospective observational study included relapsed OC patients that received niraparib as maintenance, at the time of platinum sensitive recurrence within the Italian expanded-access program. Clinical data at the time of diagnosis and at the time of recurrence were collected and analyzed. Median progression free survival (PFS) and overall survival (OS) were calculated as the time from start of niraparib treatment to subsequent radiologically confirmed relapse and death or last contact, respectively. RESULTS: Among 304 eligible patients, 260 (85%) had BRCA wild-type tumor and 36. (11.9%) were BRCA mutated. Median PFS was 9.1 months (95% CI: 6.9-11.2) and 10.3 months (95% CI: 7.0-13.5) in the BRCAwt and BRCAmut cohorts, respectively. Furthermore, median OS was 41.7 months (95% CI: 31.6-41.9) and 34.6 months (95% CI: N.E.) in the BRCAwt and BRCAmut cohorts, respectively. CONCLUSION: Data from this large real-life dataset suggested that maintenance with niraparib in the real-life setting of platinum sensitive OC recurrence is effective and well tolerated.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Musacchio L, Palluzzi E, Di Napoli M, et al. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group. Gynecol Oncol. 2024. PMID: 38277918. doi:10.1016/j.ygyno.2024.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。